AGP Executive Report
Last update: 12 hours agoWeight-Loss Treatment: Health Canada approved Eli Lilly’s GLP-1 pill, adding an oral option for Canadians seeking weight-loss treatment. Care Capacity: Manitoba says it has added more than 500 doctors since 2023, while Newfoundland and Labrador still has no physician assistants—three years after promising to hire 10. Faster Mental-Health Testing: A Canadian-funded project is developing a finger-prick test and wearable that could measure psychiatric drug levels in about 10 minutes, versus up to 15 days for lab results. Safety Alerts: Health Canada warned of possible foreign matter in PegLyte, used to prepare for medical procedures, and cautioned that some online radon detectors may give dangerously inaccurate readings. Drug Supply: Toronto’s drug-checking service found a new, poorly understood designer opioid in fentanyl samples, raising fresh concerns about the unpredictable street supply. Screening Delayed: Canada’s planned rollout of at-home cervical screening tests is now expected in 2027.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.